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Current studies of phenotype diversity by genome-wide association studies
(GWAS) are mainly focused on identifying genetic variants that influence
level changes of individual traits without considering additional alterations at
the system-level. However, in addition to level alterations of single phenotypes,
differences in association between phenotype levels are observed across differ-
ent physiological states. Such differences in molecular correlations between
states can potentially reveal information about the system state beyond that
reported by changes in mean levels alone. In this study, we describe a novel
methodological approach, whichwe refer to as genomemetabolome integrated
network analysis (GEMINi) consisting of a combination of correlation network
analysis and genome-wide correlation study. The proposed methodology
exploits differences in molecular associations to uncover genetic variants
involved in phenotype variation. We test the performance of the GEMINi
approach in a simulation studyand illustrate its use in the context of obesity and
detailed quantitative metabolomics data on systemic metabolism. Application
of GEMINi revealed a set of metabolic associations which differ between
normal and obese individuals. While no significant associations were found
between genetic variants and body mass index using a standard GWAS
approach, further investigation of the identified differences inmetabolic associ-
ation revealed a number of loci, several of which have been previously
implicated with obesity-related processes. This study highlights the advantage
of usingmolecular associations as an alternative phenotypewhen studying the
genetic basis of complex traits and diseases.1. Introduction
With the development of high-throughput genotyping technology, genome-
wide association analysis (GWAS) has become a powerful tool to examine the
genetic basis of many complex traits and common diseases. These studies
have substantially increased our knowledge of genes that influence phenotypic
variations. For instance, in obesity genetics, substantial progress has been
made with the discovery of at least 50 common and rare variants influencing
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2obesity-related traits [1–6]. Yet, despite this great success, a
large proportion of the genetic variation contributing to the
observed variability in phenotypes still remains unmapped
[7,8]. In trying to discover the ‘missing variants’, a number
of strategies have been proposed [9]. It has been suggested
that considering alternative models of genetic effects and
their influence on complex traits can help to discover some
of the missing variants [9–12].
In an earlier work [13], we highlighted the importance of
using molecular association patterns and their differences in
relation to different physiological conditions to investigate
the biological features of phenotype variation. We developed
a network-based method for the differential analysis of mol-
ecular associations and illustrated its use in the context of
prediabetes. Based on this analysis, we were able to identify
key differences in lipoprotein metabolism known to be rela-
ted to the early development of diabetic dyslipidaemias.
Importantly, these changes were not identified by comparing
changes in mean concentration levels at the early phase of dis-
ease development. These results indicate that differences in
molecular associations might provide access to unique aspects
of the underlying genetic and molecular mechanisms, being
therefore a complementary tool to unravel the biological
basis of phenotype variation.
In this study, we hypothesize that some of the undetected
variants might be associated not with changes in mean levels
of a phenotype, as studied by conventional GWAS, but with
alterations that occur at a higher system-level. To investigate
the potential use of differences in molecular dependencies to
uncover genetic variants associated with phenotype variation,
we propose a novel analytical approach to integrate metabo-
lic and genetic information, which we refer to as genome
metabolome integrated network analysis (GEMINi). A simu-
lation study is initially presented to assess the performance of
the proposed methodology. We then demonstrate the use of
our approach by investigating metabolic changes in relation
to obesity using two independent population-based cohorts,
totalling to over 5000 individuals. A recently established
serum NMR metabolomic platform [14] was applied to
quantify 38 systemic metabolites that represent various key
metabolic pathways [15].
The proposed GEMINi approach identifies potentially
new genetic components of obesity. Differences in association
between serum metabolites were identified, comprising
several metabolites linked by previous studies to the develop-
ment of obesity-related disorders. Metabolites involved in such
differential connections included all sizes of very-low-density
lipoprotein particles (VLDL) as well as several low-molecular-
weight metabolites. Further investigation of these phenotypic
differences revealed a set of genetic variants significantly associ-
ated with these differential metabolic dependencies. Several
of the associated genes have been previously implicated in
obesity-related traits. Besides the GEMINi approach, we also
performed two standard analyses. First, we looked for associ-
ations between genetic variants and body mass index (BMI) by
a conventional GWAS approach. Second, we looked for associ-
ations between mean levels of the metabolites and BMI. Using
the conventional GWAS approach, we found no associations at
a genome-wide significance level between single nucleotide
polymorphisms (SNPs) and BMI. These results highlight the
advantage of using differences in statistical association between
different molecules as an additional phenotype in the study of
common trait variation and demonstrate the applicabilityof our approach to uncover furthermolecular factors potentially
involved in the pathogenesis of complex traits.2. Material and methods
2.1. Study populations
Weused data from two large population-based cohorts, theNorth-
ern Finland Birth Cohort 1966 (NFBC1966) and the Northern
Finland Birth Cohort 1986 (NFBC1986). The methods and aims
of these studies have been published previously [16]. In brief, the
NFBC1966 includes 12 068 children with expected dates of birth
falling in between 1 January and 31 December in the two northern-
most provinces of Finland, Oulu and Lapland. Datawere collected
since pregnancy and supplemented at the age of 1, 14 and 31 years.
Blood sampleswere takenwhen individualswere 31 years old. The
NFBC1986 includes 9432 live born children with expected dates of
birth between 1 July 1985 and 30 June 1986 also in the above area.
The cohort has beenmonitored since early pregnancy until adoles-
cence. All those alivewith known address were invited to a clinical
examination at the age of 15–16 years when blood samples were
taken. The blood collections were drawn after overnight fasting
and the samples stored at 2808C. The University of Oulu Ethics
Committee and the Ethical Committee of Northern Ostrobothnia
Hospital District have approved the studies, and all participants
provided written informed consent.
2.2. Phenotype measures
For the differential network analysis, individuals were classified
into two groups: obese and non-obese according to their BMI
values. For the NFBC1966, individuals were classified as obese if
their BMI exceeded 30 kg m22. Individuals were classified as
non-obese if their BMI was equal or lower than 25 kg m22 and
equal or greater than 18.5 kg m22. For the NFBC1986, individuals
were classified as obese and non-obese by calculating the age-
and sex-specific BMI percentiles. The non-obese group includes
females with measures of BMI equal or lower than 24.05 kg m22
and equal or greater than 17.4 kg m22 and males with BMI equal
or lower than 24.2 kg m22 and equal greater than 17 kg m22
(fifth percentile to less than the 85th percentile). The obese group
includes female with BMI greater than 27.5 kg m22 and males
with BMI greater than 28.2 kg m22 (greater than the 95th percen-
tile). Individuals were excluded from analysis based on the
following criteria: non-fasting, diagnosed type I or II diabetes, preg-
nancy, lipid-lowering medication, missing data on glucose and/or
weight measures and/or height. The sample size for NFBC1966
is 3464 subjects (Nnon-obese ¼ 3023 and Nobese ¼ 441) and for
NFBC1986 it is 3791 subjects (Nnon-obese ¼ 3565 and Nobese¼ 226).
The clinical characteristics of the study groups are presented in
the electronic supplementary material, tables S1 and S2.
2.3. Metabolic data
The metabolic data for the two cohorts were acquired using the
same high-throughput serum NMR metabolomics platform
the details of which have been described previously [8,14]. Metab-
olites were selected according to feasibility of quantification by
NMR and to allow a consistent analysis across the two cohorts.
Table 1 shows the 38 metabolic measures included in the GEMINi
analysis, representing a wide variety of metabolic processes, such
as amino acid, energy and lipoprotein metabolism.
2.4. Genetic data
Only the NFBC1966 were used for the genetic analysis, because
genome-wide data for the NFBC1986 were not available. Details
for the genotyping procedure and quality control are presented
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5in reference [16]. In brief, all DNA samples were prepared and
genotyped by the Broad Institute Biological Sample Reposi-
tory. Genotyping was performed using the Illumina Infinium
370cnvDuo array. The per-sample quality control process
included analysis of duplicate samples, sex discrepancy,
sample contamination and relatedness. Of the related pairs that
shared over 20% of the genome identical by descent, the individ-
uals with less complete genotype data were excluded. Markers
were excluded if the call rate in was less than 95%, if the minor
allele frequency was less than 1% and if the p-value from a
Hardy–Weinberg equilibrium test was p, 1  1024. The final
genetic dataset included 4815 individuals and 318 443 SNPs
2.5. Statistical methods
In this study, we perform and compare two statistical procedures.
First, we perform a standard analysis of the associations between
metabolic levels and BMI using univariate linear regression and
between genetic variants and BMI following a conventional
GWAS approach. The second approach, which we refer to as
GEMINi, is a combination of (i) differential network analysis of
metabolic associations, and (ii) genome-wide correlation (GWC)
study. We assess the performance of the proposed GEMINi meth-
odology by performing a simulation study (see the electronic
supplementary material). All analyses were adjusted for sex
differences in serum metabolite levels.
2.5.1. Conventional analysis of association between obesity and
metabolic–genetic data
A conventional GWAS approach is used to test for associations
between genetic variants and BMI. The analysis is performed fol-
lowing the standard single-SNP approach where SNPs are tested
one at a time. Associations were investigated using linear
regression assuming an additive effect on the trait and including
sex as a covariate. Significant associations between genetic var-
iants and BMI measures were assessed by setting genome-wide
significance to p, 5  1028 [18].
We use linear regression to test the effect of serummetabolites
on BMI. The analyses are performed following a univariate
approach where metabolites are tested one at a time. We included
sex as a covariate to correct for sex differences in serum metabolic
profiles. To identify significant associations between serummetab-
olites and BMI, we use a conservative Bonferroni-corrected
significance level, p, 0.01/M, where M ¼ 38 denotes the total
number of serum metabolite measures.
The above analyses were conducted including all the individ-
uals for which genetic, metabolic and BMI data were available
(N ¼ 4346).
2.5.2. Genome metabolome integrated network analysis
An outline of the GEMINi methodology is presented in figure 1.
The method consists of two stages: (i) construction of the differen-
tial network, and (ii) a genome-wide correlation analysis (GWCA).
We start by performing a differential network analysis that allows
us to test whether the pattern of pairwise associations between
metabolites is the same in two physiological groups (e.g. non-
obese and obese) or whether it significantly differs across
groups. To eliminate the confounding effect of sex on the serum
metabolites, the data used for this analysis are the residuals from
a linear regression model of each metabolite on sex. To build the
differential networks, we use the same methodology presented
in reference [13]. Briefly, the underlying interdependencies
between metabolites are initially measured for each of the two
physiological groups using shrinkage estimates of partial corre-
lations [19]. To test whether the association between metabolites
significantly differs between groups, we perform a two-sample
permutation test. We used 100 000 permutations in our analysis.If the partial correlations between two given metabolites are sig-
nificantly different between the two physiological groups, then
we draw an edge in the differential network. The connections
included in the differential network are defined by setting a cut-
off on the two-tailed p-value. The power to estimate correlations
is lower than the one to estimate a change inmean levels, therefore,
to infer the differential network we set an uncorrected threshold,
p, 0.01. To validate the differential network analysis results, we
compare the network structure between the two cohorts. The repli-
cated results between cohorts are further investigated in the next
step of the analysis.
In the second step, we perform a GWCA to identify genetic
variants associated with differences in metabolic associations.
As for the standard GWAS study, all individuals for whom gen-
etic data are available were included in the analysis. To find the
desired associations, we first classify individuals according to the
number of copies of the less frequent allele carried, giving geno-
type groups A (0 copies) and B (one or two copies). SNPs are
tested one at a time. Subsequently, the correlation between
metabolites m1 and m2 is calculated for each group, rA and rB,
and differences in correlation between groups A and B is
tested. As in the differential network analysis, we eliminate the
confounding effect of sex on the serum metabolites by using
the residuals of a linear regression of the metabolite level on
sex. To test whether the two correlation coefficients, rA and rB
are the same, we use the z transform method as described in
reference [20]. To correct for multiple testing, significant associ-
ations between genetic variants and variations in metabolic
associations are determined using the genome-wide significance
threshold p, 5  1028/D, which corresponds to a genome-wide
significance level adjusted with the number of differential connec-
tions (D) identified in step one. To assess the biological significance
of our findings, identified SNPs are assigned to the nearest gene
(maximum distance 1 Mb).
All analyses were conducted in R v. 2.14.1, apart from the
conventional GWAS thatwas carried out in SNPtest v. 2.0. Compu-
tation of the partial correlation matrix was performed using the R
package GeneNet. The differential networkswere built and visual-
ized using the R package igraph. The package psych in Rwas used
to test for differences between correlation coefficients.3. Results and discussion
3.1. Conventional analysis of metabolic and
genetic data
3.1.1. Genome-wide association study analysis of BMI
We performed a standard GWAS analysis where associations
between genetic variants and BMI (as a continuous variable)
were tested. A Manhattan plot of the p-values obtained from
theGWASanalysis is presented in the electronic supplementary
material, figure S1. Although no SNPs showed association at
the genome-wide significance threshold (p, 5  1028), several
notable associations were found, of which the most significant
was a variant within a gene encoding for a transcriptional
factor-activating enhancer-binding protein two-beta (TFAP2B)
(rs987237, 6p12.3, p, 1.53  1026; see the electronic sup-
plementary material, table S3) expressed in adipose tissue.
The TFAP2B-rs987237 genetic variant has been previously
associated with a number of metabolic disorders, including
development of T2DM [21], BMI [22] and other BMI-related
phenotypes such aswaist circumference [4]. In addition, several
SNPs localized within regions previously associated with BMI
showed associations at a significance threshold of p, 0.001.
The results for a list of loci localized within known obesity
genome metabonome intergrated network analysis
individual network:
controls
individual network:
cases
differential network
cases–controls
stage 1:
differential
network analysis
stage 2:
genome-wide
correlation
analysis
(GEMINi)
Figure 1. An outline of the GEMINi methodology. (Online version in colour.)
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6genes are presented in the electronic supplementary material,
table S3.
Owing to the stringent genome-wide significance threshold
( p, 5  1028), application of the GWAS approach to a single
population frequently fails to identify statistically significant
associations. Despite the low p-values for some of the pre-
viously reported obesity-related genes, we did not reach the
genome-wide significance threshold (p, 5  1028) which
might indicate the lack of power in this cohort to identify loci
with key roles in determining variations in BMI.3.1.2. Association analysis between serum metabolites and body
mass index
We performed an inspection of the data using linear
regression to explore associations between serum metaboli-
tes and BMI. Results for the two cohorts are presented in
table 1. To facilitate comparison of the cohorts, scatter plots
for the estimated values are presented in the electronic sup-
plementary material, figure S2. The analysis shows that all
VLDL subclasses, intermediate density lipoprotein (IDL),
all low-density lipoprotein subclasses (LDL)—apart from
mean diameter for LDL particles—small high-density lipo-
protein subclass (HDL) and apolipoprotein B are positively
associated ( p, 0.01/M ) with BMI. Very large, large HDL
and mean diameter for LDL and HDL particles are inversely
associated with BMI in both cohorts. No association wasfound between BMI and apolipoprotein A in either of the
cohorts. In NFBC1966, medium HDL is inversely associated
with BMI, but shows no association in NFBC1986, which is
potentially owing to the age difference between cohorts [23].
Tests of the association between BMI and low-molecular-
weight metabolites show that alanine, glycerol, glycoprotein,
isoleucine, leucine, phenyalanine, pyruvate, tyrosine and
valine are positively associated with BMI in both cohorts,
whereas glutamine is inversely associatedwith BMI.No associ-
ation was found between BMI and acetoacetate and BMI and
urea. We observe that glucose and lactate are positively associ-
ated with BMI, but these two metabolites show no association
in NFBC1986. On the other hand, 3-hydroxybutyrate, acetate
and citrate are negatively associated with BMI and creatinine
and histidine are positively associated in NFBC1986, but
shows no association in NFBC1966.
The large number of significant associations between BMI
and the metabolite concentrations reflects the close relation-
ship between obesity and systemic metabolism. However, it
is not only the concentration levels of serum metabolites
that can change owing to variations in total body mass, but
also the dependencies between metabolites can be affected.
To investigate how metabolic associations differ between
non-obese and obese individuals and to what extent these
differences can serve as an indicator of important molecular
alteration between these physiological states, we use the
GEMINi approach.
rsif.royalsocietypublishing.org
J.R.Soc.Interface
11:20130908
73.2. Genome metabolome integrated network analysis
3.2.1. Simulation study
We carried out a simulation study to assess the performance of
the GEMINi approach (see the electronic supplementary
material). Fourdifferent scenarioswere simulatedbycombining
different values of (i) minor allele frequency, and (ii) differences
in associationsbetweenvariables across groups. These scenarios
were created to cover the rangeof variation observed in thedata.
To illustrate the predictive power of GEMINi, the receiver oper-
ating characteristic (ROC) curve analysis was used for each of
the two steps of the GEMINi approach (differential network
and GWCA) and the area under the curves determined
(AUCDiffNet and AUCGWCA). Results are presented in the
electronic supplementary material, figures S3 and S4.
Weobserve that for largedifferences in associationsbetween
variables across groups (simulation 1 and 2), the GEMINi
approach shows perfect prediction value (AUCDiffNet ¼ 1.0
and AUCGWCA ¼ 1). With small differences in associations
betweenvariablesacrossgroups (simulation3andsimulation4),
the accuracy of GEMINi drops, showing moderate prediction
values. The area under the ROC curves for simulation 3, for
the two steps of the GEMINi approach are AUCDiffNet 0.7748
and AUCGWCA 0.7793. For simulation 4, the area under the
ROC curves are AUCDiffNe ¼ 0.6885 and AUCGWCA ¼ 0.7377.
Therefore, the GEMINimethod shows a good performance
in identifying differences in associations between a genetic var-
iant and differences in pairwise associations between variables
across different groups.
3.2.2. Differential networks: non-obese and obese individuals
Differential network analysis is performed with the aim of
determining the subset of metabolic associations that signifi-
cantly differ between non-obese and obese individuals. We
examine the same metabolic variables from the two indepen-
dent cohorts (NFBC1966 and NFBC1986), and use estimates
of partial correlation as measures of metabolic dependency.
Metabolic associations that are consistently different across
the two physiological conditions (obese and non-obese)
in the two study cohorts are interpreted as obesity-related
molecular characteristics and are further investigated in
the GWCA.
The differential analysis for BMI is presented in figure 2.
Each connection in the differential network indicates that a
significant difference in the pairwise association between
two metabolic variables is found between the two physiologi-
cal conditions. To assess the robustness of differences in the
serummetabolite associations, we compare the two differential
networks (figure 2c). The differential network for NFBC1966
(figure 2a) consists of a set of 29 connected variables, which
are organized in 36 pairwise differential interactions. The
differential network for NFBC1986 (figure 2b) comprises a
group of 25 differentially connected variables, which are
organized in 19 pairwise differential interactions. We observe
similar patterns of differences in the metabolic associations in
these two differential networks. For both networks, the
majority of the connected variables represent measures of
VLDL (dark green nodes), LDL (light blue nodes), HDL
(dark orange nodes) and amino acids (pink nodes). Five
metabolites—pyruvate, histidine, lactate, tyrosine, total lipids
in small HDL—show no connections in either of the two net-
works. Five overlapping connections are observed between the
two networks (figure 2c). This overlap is significantly higherthan expected at random with p-value¼ 1.97 1024 from
a hypergeometric test with N ¼ 703 pairs, M ¼ 36, K ¼ 19,
x ¼ 5). The overlapping connections highlight differences in
the pairwise associations between VLDL measures which
occur throughout all size ranges, one measure of HDL
(M-HDL-L) and two low-molecular-weight metabolites (urea
and 3-hydroxybutyrate). Moreover, not only are a number of
connected components overlapping between the two networks,
but also the signs of the difference in partial correlations are
identical (represented as connection colours). We observe that
the correlation is significantly higher in the obese group for
small VLDL and large VLDL, ApoB and mean diameter for
VLDL, large VLDL and small VLDL, very large and medium
VLDL and extremely large VLDL and medium HDL (red
edges). On the other hand, we observe that partial correlation
between the pair urea and 3-hydroxybutyrate is significantly
lowered (blue edges) in the obese group.
A number of obesity-related differences in metabolic
associations identified here are in line with prior studies on
obesity-related traits. For instance, the central position and
abundance of VLDL-related measures in the differential
networks may reflect disregulation in VLDL metabolism.
These alterations may result from the shift from small VLDL
particles to enlarged VLDL [24]. There is also evidence to
suggest that in obesity-related dyslipidaemia an overproduc-
tion of large VLDL particles is the initiator of all sequences
of lipoprotein changes, resulting in a decrease in levels and
particle size of HDL and smaller-denser LDL particles [25].
Previous studies on obesity-related dyslipidaemias have
recognized a complex pattern of change in size and particle
concentration within the major lipoprotein classes in patients
with obesity, especially abdominal obesity [26,27]. These
disorders are related to elevated VLDL triglycerides that
trigger the shift from small VLDL to medium and large
VLDL, increased levels of small LDL and reduction in con-
centration and size of HDL. These variations in lipoprotein
particle size subclasses, which relate to dyslipidaemias associ-
ated with obesity, are captured by the differential network of
lipoprotein associations.
The relatively large number of independently replicated
results and the known relevance of the identified metabolites
to obesity provide strong support for differential association
analysis in improving our understanding of the biological
mechanisms of disease. Assuming that these metabolic dif-
ferences are related to obesity, we hypothesized that these
measures could be used as an additional phenotype to ident-
ify genetic variants associated with obesity-related traits.
To test this hypothesis, we performed a GWCA.3.2.3. Genome-wide correlation analysis of metabolic associations
The associations of 318 443 SNPs with the differences in
metabolite–metabolite partial correlations were individually
tested. Our analysis revealed 24 loci significantly associated
with differences in associations between one pair of metab-
olites, namely total lipids in medium VLDL and very-large
VLDL ( p, 5  1028/D; D ¼ 5). The identified SNPs are
localized in 18 genetic regions across 14 chromosomes.
A brief description of the identified genetic variants,
including their accession numbers, chromosomal positions,
obtained p-values, along with candidate genes associated
with the genetic marker is presented in table 2. The Manhat-
tan plot of the p-values obtained from the GWCA is
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Figure 2. The differential analysis for BMI. (Online version in colour.)
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8presented in the electronic supplementary material, figure S5.
In addition, we report the levels of association between differ-
ences in metabolic association and SNPs localized in genes
previously reported for BMI [22] (electronic supplementary
material, table S4) and SNPs previously reported to influence
human serum metabolite levels [15] (electronic supplemen-
tary material, table S5).
Several SNPs significantly associated with differences in
correlation between total lipids in medium VLDL and total
lipids in very-large VLDL are localized in or near a genepreviously implicated in the processes related to obesity or
associated traits. For instance, we identified SNP rs1334806
which is localized on chromosome 1 near a gene encoding
for dedicator of cytokinesis 7 (DOCK7). Variations in this gen-
etic region have been previously found to be implicated in the
control of lipid levels [28,29]. Another of the SNPs detected
(rs1078248) at chromosome 3p21.33 is localized near a gene
encoding for the abhydrolase domain containing five protein
(ABHD5/CG1–58). The protein encoded by this gene is
known to be linked to triglyceride (TAG) metabolism which
Table 2. Genetic loci associated with differences in metabolite–metabolite
correlations between obese and non-obese individuals. Candidate gene,
potential candidate gene in the region; Chr, chromosome; Pos, SNP position
in NCBI human genome build 36; p-value, p-value for association between
locus and variation in correlation between XL-VLDL/M-VLDL. Signiﬁcant
associations between genetic variants and variation in association between
pairs of metabolites were identiﬁed using genome-wide signiﬁcance level
threshold ( p, 5  1028/D; where D ¼ 5).
candidate
gene SNP Chr Pos p-value
DOCK rs1334806 1 62875313 1.32  10209
PPP1R12B rs12743401 1 202476648 1.01  10213
OTOF rs7592040 2 26741551 1.47  10209
ABHD5 rs1078248 3 43794357 2.36  10209
GRIA1 rs573496 5 152893433 1.94  10209
UST rs2500542 6 149331204 7.95  10210
DLC1 rs1454953 8 13315983 6.23  10210
DLC1 rs7814428 8 13324439 2.37  10210
HEY1 rs2920949 8 80869508 4.14  10209
FAM84B rs7357357 8 127189138 4.49  10209
FAM84B rs10094775 8 127197554 6.50  10209
FAM84B rs4557669 8 127306602 1.97  10209
SH2D4B rs10509433 10 83080528 2.00  10210
OR10A6 rs17315588 11 7913911 3.99  10210
OR10A6 rs1564632 11 7873288 3.23  10209
EED rs9971532 11 85929490 1.72  10209
LDHB rs1650307 12 21803770 3.11  10209
DACH1 rs7981816 13 72642843 5.33  10209
NAGPA rs2302553 16 5056295 3.06  10209
NAGPA rs3815490 16 5060568 9.01  10210
ATP4A rs8106239 19 36085358 9.14  10210
BPIFB3 rs2093066 20 31652596 7.81  10210
BPIFB3 rs378098 20 31660543 7.46  10210
MN1 rs2040699 22 28042532 3.72  10209
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9is the primary energy source in vertebrates [30]. TAGs are
stored in adipose tissue and hydrolysed into fatty acids and
glycerol and can be used by body tissues during times of
fast or energy deprivation [31]. Mutations in the gene encoding
for ABHD5 have been associated with a triglyceride storage
disease with impaired long-chain fatty acid oxidation called
Chanarin–Dorfman syndrome [32,33]. Despite the fact that
ABHD5 is involved in TGA metabolism and highly expressed
in adipose tissue, patients with Chanarin–Dorfman syndrome
are not obese [34]. No previous association between ABHD5
and obesity-related traits has been reported. Another SNP
associated with differences in correlation between total lipids
in medium VLDL and very-large VLDL is rs573496 at chromo-
some 5q33.2. This SNP is localized within a gene encoding
for glutamate receptor 1 (GRIA1). Glutamate receptors are
protein complexes formed by the combination of four different
subunits (GRIA1–GRIA4) and are known to be the main excit-
atory neurotransmitter receptors in the mammalian brain.
Regulation of glutamate receptors is influenced by leptin
levels [35].While none of the SNPs localized within genes previously
associated with BMI [22] reach the genome-wide significance
threshold ( p, 5  1028/D; see the electronic supplementary
material, table S4), we observe a relatively high association
( p, 1  1024) between a number of these SNPs and differ-
ences in association between total lipids in medium VLDL
and very-large VLDL. These SNPs are localized in five
obesity-related genetic regions, namely fat mass and obesity-
associated protein (rs4784351 with p ¼ 3.62  1025); trans-
membrane protein 18 (rs2049480 with p ¼ 8.13  1027);
neurexin-3-alpha (rs8011930 with p ¼ 2.67  1026; rs8012678
with p ¼ 2.66  1027; rs8020920 with p ¼ 8.53  1027 and
rs987644 with p ¼ 1.07  1027); cell adhesion molecule 2
gene (rs9812103 with p ¼ 1.70  1025); LDL receptor-related
protein 1B (rs2049480 with p ¼ 8.13  1027). In addition,
two SNPs localized within genes previously reported to
influence human serum metabolite levels [15] show associa-
tion at significance level p, 1  1024 with differences in
correlation between total lipids in medium VLDL and very-
large VLDL (electronic supplementary material, table S5).
These two genetic variants correspond to SNP rs560887
( p ¼ 8.95  1025), which is localized within a gene encoding
for glucose-6-phosphatase, catalytic, 2 and SNP rs261336
(p ¼ 9.31  1025), which is localized within hepatic lipase gene.4. Conclusion
While GWASs have greatly contributed to the identification
of genetic variants associated with complex traits, these var-
iants typically appear to explain only a small proportion of
the observed variability in phenotypes. In this study, we
have proposed the analysis of additional phenotypic vari-
ations such as differences in associations between metabolic
measures to aid the discovery of genetic factors involved in
complex traits. To this end, we have introduced a novel
analytical approach for the combined analysis of metabolic
and genetic information.
Initially, we examined the relationship between obesity and
serum metabolites by performing a differential analysis of
metabolic associations. Here, we investigated how metabolic
associations differ between non-obese and obese individuals
and to what extent these differences in metabolic associations
can reveal key features of obesity condition. These findings
were therefore interpreted as strong evidence of a relationship
between these metabolic associations and obesity. We per-
formed a GWCA where genetic variants were tested for
association with metabolic correlations. Unlike standard
GWAS, which did not reveal any significant associations, this
approach yielded many significant genetic loci. A clear limit-
ation of our study is the lack of a replication cohort for our
genetic findings. However, the fact that we found no associ-
ations following standard GWAS, but did find a large number
of associations using our GWC approach, many of which are
implicated in obesity-related processes, is very promising.
Moreover, the relatively low p-values for some of the previously
reported obesity-related gene lend weight to our assertion that
the GEMINi method can retrieve useful and biologically mean-
ingful relationships between genetic variants and differences
in molecular association. This study therefore highlights
the importance of investigating differences in association
between metabolites or other phenotypic indicators as an
rsif.royalsocietypublishing.org
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10additional phenotype to identify novel loci with key roles in the
pathogenesis of complex traits.
Acknowledgements. T.E. acknowledges funding from the EU Seventh
Framework Programme grants diXa (grant agreement no. 283775)
and COSMOS (grant agreement no. 312941). It was also suppor-
ted by the Finnish Foundation for Cardiovascular Research (M.A.K.),
Jenny and Antti Wihuri Foundation (A.J.K.), the Academy of Finland
(137870 for P.S.), the Responding to Public Health Challenges Research
Programme of the Academy of Finland (129429 for M.A.K.) and the
Strategic Research Funding from the University of Oulu (M.A.K.).
NFBC1966 received financial support from the Academy of Finland
(project grants nos. 104781, 120315, 129269, 1114194, Center of Excel-
lence in Complex Disease Genetics and SALVE), University Hospital
Oulu, Biocenter, University of Oulu, Finland (75617), NHLBI grant
no. 5R01HL087679-02 through the STAMPEED programme(1RL1MH083268-01), NIH/NIMH (5R01MH63706:02), ENGAGE pro-
ject and grant agreement no. HEALTH-F4-2007-201413, and the
Medical Research Council, UK (G0500539, G0600705, PrevMetSyn/
SALVE). The DNA extractions, sample quality controls, biobank up-
keeping and aliquotting was performed in the National Public
Health Institute, Biomedicum Helsinki, Finland and supported finan-
cially by the Academy of Finland and Biocentrum Helsinki. We
thank Professor (emerita) Paula Rantakallio (launch of NFBC1966
and 1986), and Ms Outi Tornwall and Ms Minttu Jussila (DNA bio-
banking). The authors acknowledge the contribution of the late
Academian of Science Leena Peltonen.
Funding statement. The work was supported by the Economic Social
Research Council (ESRC award no. ES/H016058/1 for B.V.). M.D.I.
and T.E. were partially supported by the Biotechnology and Biological
Sciences Research Council (grant ref. BB/E20372/1).Interface
11References :201309081. Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ,
Argyropoulos G, Walts B, Pe´russe L, Bouchard C.
2006 The human obesity gene map: the 2005
update. Obesity 14, 529–644. (doi:10.1038/oby.
2006.71)
2. Frayling TM et al. 2007 A common variant in the
FTO gene is associated with body mass index and
predisposes to childhood and adult obesity. Science
(New York, NY) 316, 889–894. (doi:10.1126/
science.1141634)
3. Loos RJF et al. 2008 Common variants near MC4R
are associated with fat mass, weight and risk of
obesity. Nat. Genet. 40, 768–775. (doi:10.1038/
ng.140)
4. Lindgren C et al. 2009 Genome-wide association
scan meta-analysis identifies three loci influencing
adiposity and fat distribution. PLoS Genet. 5,
e1000508. (doi:10.1371/journal.pgen.1000508)
5. Thorleifsson G et al. 2009 Genome-wide association
yields new sequence variants at seven loci that
associate with measures of obesity. Nat. Genet. 41,
18–24. (doi:10.1038/ng.274)
6. Willer CJ et al. 2009 Six new loci associated with
body mass index highlight a neuronal influence on
body weight regulation. Nat. Genet. 41, 25–34.
(doi:10.1038/ng.287)
7. Ala-Korpela M, Kangas AJ, Inouye M. 2011 Genome-
wide association studies and systems biology:
together at last. Trends Genet. 27, 493–498.
(doi:10.1016/j.tig.2011.09.002)
8. Inouye M et al. 2012 Novel loci for
metabolic networks and multi-tissue expression
studies reveal genes for atherosclerosis. PLoS
Genet. 8, e1002907. (doi:10.1371/journal.pgen.
1002907)
9. Manolio TA et al. 2009 Finding the missing
heritability of complex diseases. Nature 461,
747–753. (doi:10.1038/nature08494)
10. Struchalin MV, Dehghan A, Witteman JCM,
van Duijn C, Aulchenko YS. 2010 Variance
heterogeneity analysis for detection of potentially
interacting genetic loci: method and its
limitations. BMC Genet. 11, 92. (doi:10.1186/1471-
2156-11-92)11. Pare G, Cook NR, Ridker PM, Chasman DI. 2010 On
the use of variance per genotype as a tool to
identify quantitative trait interaction effects: a
report from the women’s genome health study.
PLoS Genet. 6, e1000981. (doi:10.1371/journal.
pgen.1000981)
12. Hothorn LA, Libiger O, Gerhard D. 2012 Model-
specific tests on variance heterogeneity for
detection of potentially interacting genetic
loci. BMC Genet. 13, 59. (doi:10.1186/1471-
2156-13-59)
13. Valca´rcel B et al. 2011 A differential network
approach to exploring differences between
biological states: an application to prediabetes.
PLoS ONE 6, e24702. (doi:10.1371/journal.
pone.0024702)
14. Soininen P et al. 2009 High-throughput serum NMR
metabonomics for cost-effective holistic studies on
systemic metabolism. The Analyst 134, 1781–1785.
(doi:10.1039/b910205a)
15. Kettunen J et al. 2012 Genome-wide association
study identifies multiple loci influencing human
serum metabolite levels. Nat. Genet. 44, 269–276.
(doi:10.1038/ng.1073)
16. Sabatti C et al. 2009 Genome-wide association
analysis of metabolic traits in a birth cohort from a
founder population. Nat. Genet. 41, 35–46. (doi:10.
1038/ng.271)
17. Benjamini Y, Hochberg Y. 1995 Controlling the false
discovery rate: a practical and powerful approach to
multiple testing. J. Roy. Stat. Soc., Ser. B 57, 289–300.
18. Risch N, Merikangas K. 1996 The future of genetic
studies of complex human diseases. Science
(New York, NY) 273, 1516–1517. (doi:10.1126/
science.273.5281.1516)
19. Schafer J, Strimmer K. 2005 A shrinkage approach
to large-scale covariance matrix estimation and
implications for functional genomics. Stat. Appl.
Genet. Mol. Biol. 4, 32. (doi:10.2202/1544-
6115.1175)
20. Revelle W. 2010 psych: procedures for personality
and psychological research. R package v. 1.0-91.
21. Maeda S et al. 2005 Genetic variations in the gene
encoding TFAP2B are associated with type 2diabetes mellitus. J. Hum. Genet. 50, 283–292.
(doi:10.1007/s10038-005-0253-9)
22. Speliotes EK et al. 2010 Association analyses of
249,796 individuals reveal 18 new loci associated
with body mass index. Nat. Gen. 42, 937–948.
(doi:10.1038/ng.686)
23. Abbott R, Yano K, Hakim A, Burchfiel C, Sharp D,
Rodriguez B, Curb JD. 1998 Changes in total and
high-density lipoprotein cholesterol over 10- and
20-year periods (the Honolulu Heart Program).
Am. J. Cardiol. 82, 172–178. (doi:10.1016/S0002-
9149(98)00310-5)
24. Adiels M et al. 2006 Overproduction of large VLDL
particles is driven by increased liver fat content in
man. Diabetologia 49, 755–765. (doi:10.1007/
s00125-005-0125-z)
25. Wang H, Peng DQ. 2011 New insights into the
mechanism of low high-density lipoprotein
cholesterol in obesity. Lipids Health Dis. 10, 176.
(doi:10.1186/1476-511X-10-176)
26. Magkos F, Mohammed BS, Mittendorfer B. 2008
Effect of obesity on the plasma lipoprotein subclass
profile in normoglycemic and normolipidemic men
and women. Int. J. Obes. 32, 1655–1664. (doi:10.
1038/ijo.2008.164)
27. Okazaki M, Usui S, Ishigami M, Sakai N, Nakamura
T, Matsuzawa Y, Yamashita S. 2005 Identification of
unique lipoprotein subclasses for visceral obesity by
component analysis of cholesterol profile in high-
performance liquid chromatography. Arterioscler.
Thromb. Vasc. Biol. 25, 578–584. (doi:10.1161/01.
ATV.0000155017.60171.88)
28. Aulchenko YS et al. 2009 Loci influencing lipid
levels and coronary heart disease risk in 16
European population cohorts. Nat. Genet. 41,
47–55. (doi:10.1038/ng.269)
29. Zhang Z, Tao L, Chen Z, Zhou D, Kan M, Zhang D, Li
C, He L, Liu Y. 2011 Association of genetic loci
with blood lipids in the Chinese population.
PLoS ONE 6, e27305. (doi:10.1371/journal.pone.
0027305)
30. Lass A et al. 2006 Adipose triglyceride lipase-
mediated lipolysis of cellular fat stores is activated
by CGI-58 and defective in Chanarin–Dorfman
rsif.royalsocietypublishing.org
11syndrome. Cell Metab. 3, 309–319. (doi:10.1016/j.
cmet.2006.03.005)
31. Jaworski K, Sarkadi-Nagy E, Duncan RE, Ahmadian
M, Sul HS. 2007 Regulation of triglyceride
metabolism. IV. Hormonal regulation of lipolysis in
adipose tissue. Am. J. Physiol. Gastrointest. Liver
Physiol. 293, G1–G4. (doi:10.1152/ajpgi.
00554.2006)
32. Akiyama M, Sawamura D, Nomura Y, Sugawara M,
Shimizu H. 2003 Truncation of CGI-58 protein causesmalformation of lamellar granules resulting in
ichthyosis in Dorfman–Chanarin syndrome.
J. Invest. Dermatol. 121, 1029–1034. (doi:10.1046/
j.1523-1747.2003.12520.x)
33. Schleinitz N, Fischer J, Sanchez A, Veit V, Harle JR,
Pelissier JF. 2005 Two new mutations of
the ABHD5 gene in a new adult case of
Chanarin–Dorfman syndrome: an uncommon
lipid storage disease. Arch. Dermatol. 141,
798–800. (doi:10.1001/archderm.141.6.798)34. Steinberg GR, Kemp BE, Watt MJ. 2007
Adipocyte triglyceride lipase expression in
human obesity. Am. J. Physiol. Endocrinol.
Metab. 293, E958–E964. (doi:10.1152/ajpendo.
00235.2007)
35. Moult PR, Cross A, Santos SD, Carvalho A-L, Lindsay
Y, Connolly CN, Irving AJ, Leslie NR, Harvey J. 2010
Leptin regulates AMPA receptor trafficking via PTEN
inhibition. J. Neurosci. 30, 4088–4101. (doi:10.
1523/JNEUROSCI.3614-09.2010)J.R.Soc.Interface
11:20130908
